IRF1 and neoplasm: There are abundant high‐frequency mutations of proteins in the INF‐γ signaling pathway in tumor cells of immunocheckpoint‐resistant patients, such as IFN‐γ receptor 1 and 2, JAK1/2, and IRF‐1 (Interferon regulator factors 1).